{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-06T03:00:56.013456+00:00","company":{"ticker":"CLPT","cik":1285550,"company_name":"ClearPoint Neuro, Inc."},"pagination":{"limit":100,"returned":9,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"material_agreement","fact_key":"b52fb95bbf5d88933c3ee57447568a2f5daf360b","cik":1285550,"ticker":"CLPT","company_name":"ClearPoint Neuro, Inc.","filed_at":"2026-01-05T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Consent to Note Purchase Agreement","agreement_type":"notes_offering","counterparty":"CALW SA LLC (as Purchaser Agent) and TPC Investments III LP (affiliate of Oberland Capital Management LLC)","effective_date":"2025-12-29","item_codes_triggered":["1.01"],"value_text":"Consent to allow internal reorganization of Swedish subsidiary and qualify IRRAS AB as an Immaterial"},"claim":"ClearPoint Neuro, Inc. amended Consent to Note Purchase Agreement with CALW SA LLC (as Purchaser Agent) and TPC Investments III LP (affiliate of Oberland Capital Management LLC) valued at Consent to allow internal reorganization of Swedish subsidiary and qualify IRRAS AB as an Immaterial (effective 2025-12-29).","evidence_excerpt":"On December 29, 2025, the Company entered into a Consent (the “Consent”) with Purchaser Agent and the 2025 Investor providing for the Company to undertake the following actions no later than January 15, 2026: (i) an internal reorganization involving the Company’s Swedish subsidiary, IRRAS AB, including the transfer of all equity interests of IRRAS USA, Inc. owned by IRRAS AB to the Company or its direct, wholly owned U.S. subsidiary in exchange for a subordinated intercompany note, and (ii) other further actions so as to allow IRRAS AB to qualify as an “Immaterial Foreign Subsidiary” under the terms of the Note Purchase Agreement.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-001581","anchor_url":"https://secwatch.observer/filing/0001193125-26-001581#claim-b52fb95bbf5d88933c3ee57447568a2f5daf360b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1285550/000119312526001581/0001193125-26-001581-index.htm"},{"fact_type":"ma_transaction","fact_key":"0f8c6ce8f13caed312e6ec22fae7c4f13ba2fc29","cik":1285550,"ticker":"CLPT","company_name":"ClearPoint Neuro, Inc.","filed_at":"2025-11-20T23:59:59+00:00","payload":{"action":"acquisition","closing_date":"2025-11-20","consideration_text":"$5,000,000 in cash and 1,325,000 shares of Company common stock","counterparty":"IRRAS Holdings, Inc.","effective_date":"2025-11-20","item_codes_triggered":["2.01"]},"claim":"ClearPoint Neuro, Inc. completed an acquisition involving IRRAS Holdings, Inc. for $5,000,000 in cash and 1,325,000 shares of Company common stock (closed 2025-11-20).","evidence_excerpt":"the “Merger”), with the Second Merger Sub surviving the Second Merger. Merger Consideration Pursuant to the Merger Agreement, the Company delivered closing consideration of $5,000,000 in cash and 1,325,000 shares of Company common stock to IRRAS shareholders (the “Closing Shares”). Earnout Consideration As additional consideration for IRRAS’ stockholders, the","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-25-290003","anchor_url":"https://secwatch.observer/filing/0001193125-25-290003#claim-0f8c6ce8f13caed312e6ec22fae7c4f13ba2fc29","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1285550/000119312525290003/0001193125-25-290003-index.htm"},{"fact_type":"shareholder_vote","fact_key":"a157c7b0e55093be2f0ee7cc21f3236afc0a6ba4","cik":1285550,"ticker":"CLPT","company_name":"ClearPoint Neuro, Inc.","filed_at":"2024-05-16T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Approval of the Fifth Amended and Restated 2013 Incentive Compensation Plan","proposal_type":"equity_plan","votes_abstain_text":"443,386","votes_against_text":"699,499","votes_for_text":"11,045,314"},"claim":"ClearPoint Neuro, Inc. shareholders approved Approval of the Fifth Amended and Restated 2013 Incentive Compensation Plan.","evidence_excerpt":"Approval of the Fifth Amended and Restated 2013 Incentive Compensation Plan. The stockholders approved the Company’s Fifth Amended and Restated 2013 Incentive Compensation Plan. The votes were cast as follows: For Against Abstentions Broker Non-Votes 11,045,314 699,499 443,386 6,843,085","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001285550-24-000061","anchor_url":"https://secwatch.observer/filing/0001285550-24-000061#claim-a157c7b0e55093be2f0ee7cc21f3236afc0a6ba4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1285550/000128555024000061/0001285550-24-000061-index.htm"},{"fact_type":"shareholder_vote","fact_key":"b37efee36942da50e4d0c10d65593e8c4f8f3006","cik":1285550,"ticker":"CLPT","company_name":"ClearPoint Neuro, Inc.","filed_at":"2024-05-16T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Advisory approval of executive compensation","proposal_type":"say_on_pay","votes_abstain_text":"431,796","votes_against_text":"629,515","votes_for_text":"11,126,888"},"claim":"ClearPoint Neuro, Inc. shareholders approved Advisory approval of executive compensation.","evidence_excerpt":"Advisory approval of executive compensation. The stockholders, on an advisory basis, approved the compensation of the Company’s executives. The votes were cast as follows: For Against Abstentions Broker Non-Votes 11,126,888 629,515 431,796 6,843,085","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001285550-24-000061","anchor_url":"https://secwatch.observer/filing/0001285550-24-000061#claim-b37efee36942da50e4d0c10d65593e8c4f8f3006","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1285550/000128555024000061/0001285550-24-000061-index.htm"},{"fact_type":"shareholder_vote","fact_key":"281b62957de01dfc723f1808bff9bf3a1959b5f2","cik":1285550,"ticker":"CLPT","company_name":"ClearPoint Neuro, Inc.","filed_at":"2024-05-16T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-12-31","outcome":"passed","proposal_text":"Ratification of Cherry Bekaert LLP as independent registered public accounting firm for 2024","proposal_type":"auditor_ratification","votes_abstain_text":"21,001","votes_against_text":"68,614","votes_for_text":"18,941,669"},"claim":"ClearPoint Neuro, Inc. shareholders approved Ratification of Cherry Bekaert LLP as independent registered public accounting firm for 2024 at the 2024-12-31 meeting.","evidence_excerpt":"Ratification of Independent Registered Public Accounting Firm. The stockholders ratified the appointment of Cherry Bekaert LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2024. The votes were cast as follows: For Against Abstentions Broker Non-Votes 18,941,669 68,614 21,001 —","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001285550-24-000061","anchor_url":"https://secwatch.observer/filing/0001285550-24-000061#claim-281b62957de01dfc723f1808bff9bf3a1959b5f2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1285550/000128555024000061/0001285550-24-000061-index.htm"},{"fact_type":"shareholder_vote","fact_key":"a542e2871eda86756ea931934508bd39fa2ce42d","cik":1285550,"ticker":"CLPT","company_name":"ClearPoint Neuro, Inc.","filed_at":"2024-05-16T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":null,"outcome":"passed","proposal_text":"Election of eight directors to serve until the 2025 annual meeting","proposal_type":"director_election","votes_abstain_text":null,"votes_against_text":"See individual nominee tallies","votes_for_text":"See individual nominee tallies"},"claim":"ClearPoint Neuro, Inc. shareholders approved Election of eight directors to serve until the 2025 annual meeting.","evidence_excerpt":"Election of Directors. The following named persons were elected as directors of the Company to serve until the 2025 annual meeting of stockholders or until their successors have been duly elected and qualified or until their earlier death, resignation, disqualification or removal. The votes were cast as follows: Name For Withheld Broker Non-Votes Joseph M. Burnett 12,037,171 151,028 6,843,085 R. John Fletcher 11,734,172 454,027 6,843,085 Lynnette C. Fallon 11,780,550 407,649 6,843,085 Pascal E.R. Girin 11,771,794 416,405 6,843,085 B. Kristine Johnson 11,730,889 457,310 6,843,085 Matthew B. Klein 11,850,463 337,736 6,843,085 Linda M. Liau 11,716,020 472,179 6,843,085 Timothy T. Richards 11,625,429 562,770 6,843,085","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001285550-24-000061","anchor_url":"https://secwatch.observer/filing/0001285550-24-000061#claim-a542e2871eda86756ea931934508bd39fa2ce42d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1285550/000128555024000061/0001285550-24-000061-index.htm"},{"fact_type":"earnings_release","fact_key":"03c6f8b9a1e21a2f59f7c53117f3b148b1596e43","cik":1285550,"ticker":"CLPT","company_name":"ClearPoint Neuro, Inc.","filed_at":"2024-05-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the first quarter ended March 31, 2024","report_date":"2024-05-07","result_type":"reported_results","revenue_text":"$7.6 million"},"claim":"ClearPoint Neuro, Inc. reported the first quarter ended March 31, 2024 results: revenue $7.6 million. Guidance reaffirmed.","evidence_excerpt":"precise navigation to the brain and spine, today announced financial results for its first quarter ended March 31, 2024. First Quarter Highlights • Reported quarterly revenue of $7.6 million, a 41% year-over-year increase; • Increased biologics and drug delivery revenue to $4.3 million, a 61% year-over-year increase; • Partner PTC Therapeutics submitted first-ever","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001285550-24-000049","anchor_url":"https://secwatch.observer/filing/0001285550-24-000049#claim-03c6f8b9a1e21a2f59f7c53117f3b148b1596e43","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1285550/000128555024000049/0001285550-24-000049-index.htm"},{"fact_type":"earnings_release","fact_key":"eff57661ee7ffd7c957890d0ae9de25e0c0fda3f","cik":1285550,"ticker":"CLPT","company_name":"ClearPoint Neuro, Inc.","filed_at":"2024-03-12T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fiscal year ended December 31, 2023","report_date":"2024-03-12","result_type":"reported_results","revenue_text":"$24.0 million"},"claim":"ClearPoint Neuro, Inc. reported the fiscal year ended December 31, 2023 results: revenue $24.0 million. Guidance reaffirmed.","evidence_excerpt":"Reported revenue of $24.0 million for the full year 2023","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001285550-24-000030","anchor_url":"https://secwatch.observer/filing/0001285550-24-000030#claim-eff57661ee7ffd7c957890d0ae9de25e0c0fda3f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1285550/000128555024000030/0001285550-24-000030-index.htm"},{"fact_type":"earnings_release","fact_key":"3babfbd2fed77dd4c1ae331b038a529368c64ade","cik":1285550,"ticker":"CLPT","company_name":"ClearPoint Neuro, Inc.","filed_at":"2024-03-12T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fourth quarter ended December 31, 2023","report_date":"2024-03-12","result_type":"reported_results","revenue_text":"$6.8 million"},"claim":"ClearPoint Neuro, Inc. reported the fourth quarter ended December 31, 2023 results: revenue $6.8 million. Guidance reaffirmed.","evidence_excerpt":"Reported fourth quarter 2023 revenue of $6.8 million","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001285550-24-000030","anchor_url":"https://secwatch.observer/filing/0001285550-24-000030#claim-3babfbd2fed77dd4c1ae331b038a529368c64ade","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1285550/000128555024000030/0001285550-24-000030-index.htm"}]}